Teva launched the first and only generic version of Sandostatin LAR Depot, in the United States. Octreotide acetate for injectable suspension – the generic version of Sandostatin LAR Depot – is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome. Sandostatin LAR Depot had annual sales of $826M as of July 2024. Octreotide acetate for injectable suspension, the generic version of Sandostatin LAR Depot, is a prescription medication used in patients in whom initial treatment with octreotide acetate injection has been shown to be effective and tolerated for: long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy, is not an option to reduce GH and IGF-1 levels to normal; long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors; long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva announces new analysis from European cohort of RIM-TD study
- Teva presents new Phase 3 efficacy, safety data from SOLARIS trial
- EU set to fine Teva for disparaging rival to Copaxone, Reuters reports
- Teva case for multiple expansion ‘remains solid,’ says Jefferies
- Teva provides update on Olanzapine LAI trial